COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
RETRANSMISSION: DLT Resolution Inc. Initiates Strategic Acquisition, Securing 19.9% Stake in Ciscom Corp
DLT Resolution Inc. announces acquisition of 19.9% stake in Ciscom Corp. to drive growth strategy. Planned multiple add-on acquisitions to expand market footprint and empower future growth in ICT sector -
COMMUNIQUÉ DE PRESSE
Eventeny Unveils Ticket Reselling and Seat Select, an Innovative Pairing That Will Empower Organizers and Attendees to Get the Most Out of Event Registration
Eventeny introduces Ticket Reselling and Seat Select features to enhance event registration. Ticket Reselling minimizes refunds and disputes while Seat Select offers customizable seating charts for a personalized event experience -
COMMUNIQUÉ DE PRESSE
Allure Esthetic Plastic Surgery's Dr. Javad Sajan Elevates New, Advanced Method of Breast Augmentation
Dr. Sajan at Allure Esthetic Plastic Surgery introduces the Transumbilical Breast Augmentation Technique (TUBA) to reduce the risk of breast implant complications and reactions, offering a safer and less invasive method for patients -
COMMUNIQUÉ DE PRESSE
Sterling Metals Signs Definitive Agreement to Acquire the Copper Road Project in Ontario
Sterling Metals Corp. announces acquisition of 100% interest in the Copper Road Project from Copper Road Resources Inc. Located in Ontario, the project shows high-potential brownfield copper-moly-silver-gold mineralization -
-
COMMUNIQUÉ DE PRESSE
Original-Research: Scherzer & Co. AG (von GSC Research GmbH): Kaufen
Analyse von GSC Research GmbH zu Scherzer & Co. AG basierend auf den vorl ufigen Gesch ftszahlen 2023. Empfehlung zum Kauf mit Kursziel von 3,00 Euro. Analyse zeigt Potenzial f r berdurchschnittliche Performance -
-
COMMUNIQUÉ DE PRESSE
Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research reaffirms BUY rating for CEL-SCI Corporation (ISIN: US1508376076) with USD 8.40 price target. Completion of US manufacturing facility for lead drug Multikine expected in H1 2024
